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Abstract
Impaired cerebrovascular reactivity precedes histological and clinical evidence of CADASIL in animal models. We aimed
to more fully characterise peripheral and cerebral vascular function and reactivity in a cohort of adult CADASIL patients,
and explore the associations of these with conventional clinical, imaging and neuropsychological measures. A total of 22
adults with CADASIL gave informed consent to participate in an exploratory study of vascular function in CADASIL.
Clinical assessment, comprehensive vascular assessment, MRI and neuropsychological testing were conducted. We
measured cerebral vasoreactivity with transcranial Doppler and arterial spin labelling MRI with hypercapnia challenge.
Number and volume of lacunes, subcortical hyperintensity volume, microbleeds and normalised brain volume were
assessed on MRI. Analysis was exploratory and examined the associations between different markers. Cerebrovascular
reactivity measured by ASL correlated with peripheral vasoreactivity measured by flow mediated dilatation. Subjects with
5 lacunes were older, with higher carotid intima-media thickness and had impaired cerebral and peripheral vasoreac-
tivity. Subjects with depressive symptoms, disability or delayed processing speed also showed a trend to impaired
vasoreactivity. Impaired vasoreactivity and vascular dysfunction may play a significant role in the pathophysiology of
CADASIL, and vascular assessments may be useful biomarkers of severity in both longitudinal and clinical trials.
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Introduction
Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy
(CADASIL) is the most common monogenetic small
vessel disease and results in stroke and cognitive
impairment.1 CADASIL is caused by mutations of
NOTCH3, which codes for a receptor expressed in vas-
cular smooth muscle cells and pericytes,2 involved in
regulation of cerebral blood ﬂow (CBF).3 Although
clinical manifestations are conﬁned to the brain, arter-
iopathy is detected throughout the body.4
Coincident with histological abnormalities, vascular
dysfunction occurs. Human studies suggest reduced
CBF, which may precede symptoms,5 and impairment
of cerebrovascular reactivity (CVR) within white
matter hyperintensities on brain magnetic resonance
imaging (MRI).6 Impaired CVR was associated with
increased hyperintensity volume after seven years, but
the clinical relevance of this remains unclear.7
Peripheral vascular function may also be impaired
in vivo,8 and ex vivo.9 Other measures of vascular dis-
ease such as carotid intima-media thickness10 and
blood pressure (BP)11 may inﬂuence disease severity.
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Genetic testing, and the long presymptomatic phase,
potentially allow for early intervention. MRI
demonstrates features of small vessel disease, including
hyperintensities, lacunes, microbleeds and atrophy.
Whilst lacunes and atrophy are associated with
cognitive deterioration,12 the wide inter-individual vari-
ation and slow rate of progression potentially limit the
utility of structural MRI features as biomarkers of dis-
ease progression.13 Vascular function may oﬀer an
alternative index of disease activity and progression.
We aimed to explore cerebral and peripheral vascu-
lar function and reactivity in a cohort of adult
CADASIL patients to give a more complete view of
this than performed in previous studies. We investi-
gated associations with structural MRI, clinical and
neuropsychological markers of disease, and discuss
the role for potential biomarkers in clinical trials.
Material and methods
Study cohort
Subjects aged 18 years or over with a genetic diagnosis
of CADASIL were eligible. Exclusion criteria included
contraindications to MRI, current use of calcium chan-
nel blockers or angiotensin-converting enzyme inhibi-
tors, and type II respiratory failure. Subjects provided
written, informed consent. The study was approved by
the West of Scotland Research Ethics Service (12/WS/
0295). The study was governed by standards laid down
in the Helsinki Declaration of 1975 (and as revised in
1983).
Study visits were: (1) Transcranial Doppler (TCD)
ultrasound and clinical assessment, (2) peripheral vas-
cular tests, (3) MRI with respiratory challenge, and (4)
neuropsychology. Visit 1 always took place ﬁrst but
otherwise visits took place in any order. Subjects were
instructed not to take caﬀeine, nicotine or alcohol for
4 h prior to visits 1, 2 and 3.
Visit 1: Clinical assessment and TCD ultrasound
Details regarding medical history, medication and car-
diovascular risk factors were collected. Neurological
impairment was assessed using the National Institute
of Health Stroke Scale (NIHSS).14 Global disability
was assessed with the Rankin Focused Assessment
tool to derive the categorisation on the modiﬁed
Rankin Scale (mRS).15,16 Concurrent presence of anx-
iety or depressive symptoms was recorded with the self-
rating Hospital Anxiety and Depression Scale (HADS,
GL Assessment Limited, London).17
TCD of the middle cerebral arteries in the transtem-
poral window was performed with a ST3/Model PMD
150 (Spencer Technologies, Seattle, USA) with
continuous monitoring (IntelliVue MP30, Philips
Medical Systems, the Netherlands) including oxygen
saturation and end-tidal CO2 (EtCO2). BP was mea-
sured before, during and after CO2 delivery. An anaes-
thetic mask (Quadralite mask, ref 7193, Intersurgical
Ltd) attached with a harness (Ref 2224, Intersurgical
Ltd) was ﬁtted to the patient, and attached to a unidir-
ectional breathing circuit (Ref 2013014, Intersurgical
Ltd). Mean ﬂow velocity (MFV; cm/s) was recorded
continuously whilst the subject received: 3min room
air – 3min 6% CO2/air at 40L/min (BOC Medical,
Manchester, UK, Medical Special’s Licence Number
ML/0735/01) – 3min room air. Traces were excluded
if EtCO2 was not maintained during the hypercapnia
challenge suggesting a circuit leak. If both right and left
measurements were available, the mean was used.
Cerebrovascular reactivity (CVRTCD) was calculated
as a percentage change in MFV per change in EtCO2.
CVRTCD ¼MFVhypercapnia MFVnormocapnia
MFVnormocapnia
 100
EtCO2 hypercapnia  EtCO2 normocapnia
Visit 2: Peripheral vascular tests
All peripheral vascular tests took place within a tempera-
ture controlled room (22–24C) and were performed and
analysed by a single rater (FM). Body mass index (BMI)
was calculated. Supine BP and heart rate were measured
following 10min of rest. Pulse wave analysis (PWA, as
the augmentation index at 75 beats per minute, AI75)
and pulse wave velocity (PWV) assessed large vessel
arterial stiﬀness; carotid ultrasound with carotid
intima-media thickness (CIMT) assessed generalised ath-
erosclerosis; and non-invasive peripheral artery tonome-
try (reactive hyperaemia index, RHI) and ﬂow mediated
dilatation (FMD) of the brachial artery assessed endo-
thelial function (see Figure 1 for example). Further
details and background about methods are shown in
supplementary materials.
Visit 3: MRI
Scans were obtained on a 3T MRI GE Signa Excite HD
scanner with an 8-channel head coil (GE Medical
Systems, Milwaukee, Wisconsin). Sequences included
(i) axial T2-weighted FLAIR (repetition time/inversion
time/echo time¼ 10,000/2250/140ms, slice thick-
ness¼ 5mm, interslice gap¼ 1.5mm, matrix
384 256, acquisition time¼ 3:20min); (ii) axial T1-
weighted FSPGR BRAVO (repetition time/inversion
time/echo time¼ 9.0/450/3.6ms, slice thickness¼ 1mm,
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no interslice gap, ﬂip angle¼ 12, matrix 320 320,
acquisition time¼ 4:28min); (iii) axial T2*-weighted
susceptibility angiography (SWAN) (repetition time/
echo time¼ 40/25ms, slice thickness 3.6mm, slice
gap¼ 1.8mm, ﬂip angle 15, matrix 320 224, acquisi-
tion time¼ 2:16min); (iv) sagittal Inhance 3D velocity
MR angiography (repetition time/echo time¼ 8.6/
3.54ms, slice thickness¼ 1.2mm, ﬂip angle¼ 8,
matrix 320 224, acquisition time¼ 3:11min).
Diﬀusion tensor imaging and resting state BOLD
scans were also obtained but not analysed in this study.
All Arterial Spin Labeling (ASL) scans took place
between 9:30 am and 13:45 pm. Subjects were ﬁtted
with a close-ﬁtting mask (Intersurgical Ltd, Ref
1141). Expiratory ports were closed and gauze swabs
and tape were used to improve ﬁt. The mask was con-
nected to the unidirectional breathing circuit (Ref
2013014, Intersurgical Ltd). Observations (oxygen sat-
uration, respiratory rate, heart rate) and gas concentra-
tions were measured with an MRI compatible monitor
(Veris Vital Signs Monitor, MEDRAD, Indianola,
USA). A 3D pseudo-continuous ASL scan was per-
formed with the subject receiving 15L/min air. The
subject was then switched to receive 40L/min of
6%CO2/air. After 2min, the ASL scan was repeated.
The protocol was as follows: repetition time¼ 4864ms,
echo time¼ 10.1ms, labelling duration¼ 1500ms,
post-labelling delay time¼ 2025ms, slice thickness
3.5mm, matrix 128 128, ﬂip angle 155, NEX 3.0,
time¼ 4.42min. In the ﬁrst three patients, a neurovas-
cular head coil (eight-channel) was used when
obtaining the ASL scans.
MRI analysis
Cerebral microbleeds, lacunes and subcortical hyperin-
tensities (SHs) were deﬁned as per recent neuroimaging
standards.18 The Microbleed Anatomical Rating Scale
(MARS), a validated scale, was used to classify micro-
bleeds.19 One rater (FM) scored all scans twice: for any
scans where there was discrepancy, a second person
reviewed the scan (KD). Lacunes were deﬁned as sub-
cortical, ﬂuid-ﬁlled cavities (signal similar to
cerebrospinal ﬂuid) of between 3mm and 15mm in
diameter.18 Lacunes were segmented and their volume
calculated on T1-weighted images using 2D and 3D
Figure 1. Assessing peripheral and cerebral vasoreactivity. (a) Endothelium-dependent vasodilatation was assessed using a ple-
thysmographic method (EndoPat-2000). Following occlusion, hyperaemia should occur if there is normal endothelial function (ai),
whereas absence of hyperaemia suggests endothelial dysfunction (aii). (bi) Endothelial function was also assessed with ultrasonography
of the brachial artery with change in diameter being measured with automated identification of the intima-media layer (green and pink
box) (bii). Following distal artery occlusion, a flow-mediated dilatation (FMD) of the brachial artery should occur, with a gradual return
to baseline, and an example of this is shown. (ci) Cerebral reactivity challenges were performed using a hypercapnic challenge
delivered with a unidirectional circuit and mask. (cii) Transcranial Doppler ultrasound assessed mean flow velocity (MFV) over a 9-min
test period, with 3min of 6% CO2. Cerebrovascular reactivity was calculated as the change in velocity between the last minute of
hypercapnia and the baseline. Flow in the right middle cerebral artery (MCA; black line) and end-tidal CO2 (red line) are shown.
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thresholding tools (Analyze v 11.0, AnalyzeDirect Inc.,
USA). Lacune volume was normalised (NLV, %) to
intracranial cavity volume. Intraclass correlation for
this method for 20 scans was 0.934 (0.845–0.973).
FMRIB software library v 5.0 tools including
SIENAX, were used to determine intracranial cavity
volume from SWAN images and normalised brain
volume (NBV) from T1-weighted images.20–22
Hyperintense signal abnormalities on FLAIR in white
matter, grey matter and brainstem were termed
SHs.18To calculate the SH volume, a skull stripped
FLAIR image was created20,21,23 and the mode inten-
sity of this image, multiplied by 1.3, was used to thresh-
old the image, with manual removal of cortical voxels if
required24 to create an SH mask. SH volume was nor-
malised (NSH, %) by intracranial cavity volume.
Intraclass correlation for ﬁve scans repeated by one
rater with this method was 0.999 (0.991  1).
MR angiography was inspected by a neuroradiolo-
gist (CS) for evidence of vessel stenosis.
ASL
Structural scans, SH masks and ASL scans were co-
registered (Analyze v 11). Quantitative CBF maps were
generated using an in house macro for Image J
(Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, http://imagej.nih.
gov/ij/, 1997–2014.) The transformed T1-weighted
image was segmented into parenchyma, grey, and
white matter masks.23 SH pixels were removed from
grey and white matter masks. Masks were applied to
CBF maps (see Figure 2).
Change in CBF (%CBF) was corrected for change
in EtCO2 to calculate cerebrovascular reactivity
(CVRASL)
CVRASL ¼ CBFhypercapnia  CBFnormocapnia
CBFnormocapnia
 100
EtCO2 hypercapnia  EtCO2 normocapnia
Expiratory gas data were used if EtCO2 whilst
breathing air was between 3.5 and 6.5%, suggesting
reasonable mask seal.
Visit 4: Neuropsychological assessment
Neuropsychological testing was conducted by a special-
ist clinical neuropsychologist (BC). Assessment
focussed on processing speed and executive function
as the primary cognitive domains aﬀected in
CADASIL. Composite scores were calculated as the
mean of the domain-speciﬁc individual tests after
conversion of raw scores to standardised scores
(z-scores, corrected for age or age and education, with
reference to published normative tables). The process-
ing speed composite score was calculated from the
Symbol-Digit Modalities test and Trail-making test
Part A. The executive function composite score was
calculated from the Similarities sub-test of the
Wechsler Adult Intelligence Scale, the FAS letter ﬂu-
ency test, the Trail-making Test Part B and the Stroop
Neuropsychological Screening Test. For both compos-
ite scores, a higher score indicates better performance.
Subjects included in the analysis had no known visual
disabilities that would impair performance, but one
subject was unable to complete some tests due to dys-
arthria and inability to hold a pen.
Statistical analysis
Statistical analysis was performed with IBM SPSS
Version 21 (IBM Corp, Armonk, NY, USA). This
was an exploratory study so multiple variables were
included and compared. Variables investigated
included age, systolic BP, PWV, FMD, CIMT, RHI,
CVRTCD, CBF and CVRASL in diﬀerent brain regions.
Clinical outcomes were: history of stroke, processing
speed and executive function. Outcomes of clinical
scales were dichotomised: NIHSS (0 or 1), mRS
(0–1 or 2) and HADS depression and anxiety scores
(0–7 or 8)
Continuous variables were compared with
Spearman’s rank correlation. Regional CBF was com-
pared with paired t-tests. Structural MRI variables
were dichotomised by their median. Normality was
tested with Shapiro-Wilk. For categorical outcomes,
normally distributed data were tested with independent
t-test, and non-normally distributed data with inde-
pendent sample Mann Whitney U tests. Results were
expressed as mean (standard deviation, SD) unless
otherwise stated. Although multiple comparisons were
used, this was an exploratory study so signiﬁcance was
set at p< 0.05. Multivariate testing was not undertaken
due to small sample size.
Results
A total of 22 subjects from 19 pedigrees were recruited.
There were nine diﬀerent mutations, in ﬁve diﬀerent
exons. Subject demographics, risk factors, history and
imaging characteristics are reported in Table 1. All sub-
jects attended all study visits over a mean of 79 days
(standard deviation 26 days). There was no evidence of
extracranial vessel disease on MRA in 20/22 (one sub-
ject aged 30 years did not undergo MRA due to tech-
nical problems; one scan had movement artefact, but
the patient had normal carotid ultrasound).
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CBF measured by ASL was available in 19 subjects
(one not performed, two excess head rotation prevented
analysis). CVRASL was available in 13 patients. Study
cohort vascular measurements are shown in Table 2.
Blood flow and reactivity
CBF was highest in grey matter compared to white
matter (p< 0.001) or SHs (p< 0.001; Table 2). CBF
and MFV were not signiﬁcantly correlated (grey
matter CBF, n¼ 18, rs¼ 0.320, p¼ 0.195), or related
to age (grey matter CBF, n¼ 19, rs¼0.383,
p¼ 0.106; MFV, n¼ 21, rs¼0.370, p¼ 0.099).
Hypercapnic-induced changes in blood ﬂow varied
widely among patients but, intra-subject measures in
individual brain regions were highly correlated with
each other (rs values between 0.940 and 0.995).
Grey matter CVRASL showed a non-signiﬁcant trend
towards association with CVRTCD (n¼ 13, rs¼ 0.484,
p¼ 0.094). FMD was positively correlated with
CVRASL (parenchyma, n¼ 12, rs¼ 0.615, p¼ 0.033;
grey matter, n¼ 12, rs¼ 0.566, p¼ 0.055).
Resting systolic BP was positively correlated with all
measures of brain reactivity (grey matter CVRASL,
n¼ 13, rs¼ 0.567, p¼ 0.043) and CVRTCD (n¼ 21,
rs¼ 0.462, p¼ 0.035). BP did increase during hypercap-
nia TCD challenge (baseline 119 11; max during
hypercapnia 127 12mmHg, p< 0.01) but change in
BP did not correlate with reactivity measures.
Measures of peripheral vasoreactivity, brachial
FMD and RHI, did not correlate with each other
(n¼ 17, rs¼0.184, p¼ 0.479).
Current smokers or those with a greater than 20
year pack history, had higher RHI than those who
Figure 2. Cerebral blood flow and vasoreactivity – ASL MRI. (a) Generated CBF maps were masked with brain, grey matter, white
matter and subcortical hyperintensity masks and the average in each mask recorded. Masks were created using T1 and FLAIR images.
Scale bar shown for CBF in ml/100 g/min (b) CBF in brain, grey matter, white matter and subcortical hyperintensities whilst breathing
air (line) and 6% CO2 (dashed line). (c) Patients with five or more lacunes had (i) lower cerebral vasoreactivity and (ii) lower peripheral
vasoreactivity (brachial FMD). There were also (iii) older and had higher carotid intima-media thickness (iv). Boxplot shows medians,
quartiles, and extreme values.
CBF: cerebral blood flow; GM: grey matter; WM: white matter; SH: subcortical hyperintensity.
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had never smoked (1.9 0.5 v 2.6 0.8; p¼ 0.032).
Subjects not on statins tended to be younger (42
years 13 v 52 9; p¼ 0.049) but other vascular
measures did not vary.
Is peripheral and cerebral vessel function
associated with structural MRI markers?
Associations between structural MRI markers and vas-
cular measures are shown in Table 3. A lower NBV was
associated with increased PWV and CIMT, and lower
CVR. The presence of many lacunes (5) was asso-
ciated with higher age, increased CIMT, lower FMD
and lower CVR (Figure 2). There was a trend towards
patients with microbleeds being older (absence 46yrs
(11); presence 53 (11); p¼ 0.08), but otherwise they
were not related to other vascular variables.
Normalised SH volume was not signiﬁcantly associated
to any vascular variable. Gender and smoking history
had no eﬀect on structural MRI markers.
Investigate how vasoreactivity relates to clinical
and neuropsychological markers of disease
Subjects with depressive symptoms (HADS 8)
showed a non-signiﬁcant trend towards reduced
CVRASL but this did not reach statistical signiﬁcance
(HADS 8, n¼ 3, grey matter CVR ASL 1 (5);
HADS< 8, grey matter CVRASL 12 (9); p¼ 0.086).
Disabled patients (mRS 2) showed similar results,
Table 1. Study cohort characteristics (n¼ 22).
Characteristics Cohort (n¼ 22)
Demographic characteristics
Age, mean (SD) (years) 49.6 (11.2)
Female, n (%) 11 (50)
Clinical scores
NIH stroke scale,
median (range)
0 (0–3)
Modified Rankin Score,
median (range)
0 (0–3)
Anxiety score, median
(range)
6 (2–16)
Depression score,
median (range)
4 (0–18)
Clinical features, n (%)
Stroke or TIA 11 (50)
Migraine 21 (95)
Depression 10 (45)
Urinary incontinence 4 (18)
Seizures 0 (0)
Vascular risk factors, n (%)
Current or ex-smoker 11 (50)
Hypertensiona 0 (0)
Hypercholesterolaemiab 13 (59)
Diabetes mellitus 0 (0)
Medication, n (%)
Statin 16 (73)
Antiplatelet 18 (82)
Antidepressant 8 (36)
Beta-blockerc 2 (9)
Imaging characteristics,
mean SD, range, mediand
No. of lacunes 9 10, 0–34, 5
No. of microbleeds 2 3, 0–10, 0
Normalised lacune
volume (NLV), %
0.04 0.04, 0–0.15, 0.02
Normalised SH volume
(NSH), %
6.0 3.9, 1.0–15.5, 5.2
Normalised brain
volume (NBV), L
1.5 0.1, 1.4–1.8, 1.5
SD: standard deviation; NIH: National Institute of Health; TIA: Transient
Ischaemic Attack. aDefined as systolic BP> 140 or diastolic
BP> 90mmHg on two or more occasions, or reported in patients’ med-
ical records. bDefined as a recorded reading of cholesterol >5.2mmol/L.
cPrescribed for migraine prevention rather than blood pressure control.
dT1 and FLAIR movement artefact in one subject; two subjects were
excluded from microbleed assessment due to incorrect slice thickness.
Table 2. Study cohort vascular measurements.
Number Mean (SD)
SBP, mmHg 22 120 (11)
PWA, augmentation index
at 75 bpm
22 17 (13)
PWV, m/s 21 7.5 (1.1)
RHI, % 20 2.1 (0.7)
CIMT, mm 21 0.64 (0.1)
FMD, % 18 4.1 (1.9)
MFV, cm/s 21 40 (9.5)
Brain parenchyma CBF,
ml/100 g/min
19 46 (8.6)
Grey matter CBF, ml/
100 g/min
19 51 (9.4)
White matter CBF, ml/
100 g/min
19 43 (7.6)
Subcortical hyperintensity
CBF, ml/100 g/min
19 30 (5.6)
CVRTCD, % 21 19 (11.2)
Grey matter CVRASL, % 13 9.5 (9.3)
Subcortical hyperintensity
CVRASL, %
13 9.0 (7.7)
SBP: systolic blood pressure; BMI: body mass index; PWA: pulse wave
analysis; PWV: pulse wave velocity; RHI: reactive hyperaemia index;
CIMT: carotid intima-media thickness; FMD: flow mediated dilatation;
MFV: mean flow velocity; CBF: cerebral blood flow.
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but all also had high depressive symptoms. Vascular
measures did not vary with NIHSS or anxiety scores.
Processing speed declined with high NLV (n¼ 20,
rs¼0.667, p¼ 0.001) and lower NBV (n¼ 20,
rs¼ 0.512, p¼ 0.021). Impaired processing speed was
associated with higher CIMT (n¼ 20, rs¼0.463,
p¼ 0.04) and non-signiﬁcantly with lower CVRASL
(grey matter n¼ 13, rs¼ 0.50, p¼ 0.082). Impaired
executive function was non-signiﬁcantly associated
with a lower NBV (n¼ 19, rs¼ 0.441, p¼ 0.059) but
no other measures. See supplementary materials for
full results.
Discussion
In this exploratory study, we comprehensively evalu-
ated multimodal indices of cerebral and peripheral vas-
cular function and investigated how these correlate to
clinical and radiological features in CADASIL.
As far as we are aware, this is the ﬁrst study using
ASL in CADASIL, and we have demonstrated its feasi-
bility and potential utility. Measured grey matter CBF
of 51ml/100 g/min is consistent with the literature,25
and regional diﬀerences were detectable, with the tech-
nique oﬀering the advantages of repeatability, quanti-
ﬁcation and no need for contrast administration.
Combining ASL with a hypercapnia challenge, again
novel in this disease, we showed impaired cerebral
vasoreactivity, was related to number of lacunes and
brain atrophy, important correlates of clinical impair-
ment.26 Patients with greater disability, depression and
impaired processing speed, also tended to have worse
cerebral vasoreactivity.
Peripheral vasoreactivity was also impaired in
patients with higher numbers of lacunes. Whether
impaired cerebral vasoreactivity pre-exists, or is subse-
quent to, the development of lacunes cannot be
answered in this cross-sectional study. The ﬁnding of
co-existent peripheral vasoreactivity does suggest, how-
ever, that abnormal vessel responsiveness in CADASIL
is not solely secondary to brain damage, and may thus
represent a primary process in disease evolution.
Peripheral vascular testing is easier to undertake, par-
ticularly in disabled individuals, and tests have been
used as biomarkers in cardiovascular studies.27,28 It
could therefore be considered as a useful adjunct in
clinical trials. Previous studies have not demonstrated
diﬀerences in FMD between CADASIL patients and
controls8,29 whereas we found it to be associated with
lacunes. We measured vessel diameter continuously for
5min after cuﬀ deﬂation, rather than at discrete time
points,29 allowing us to characterise vessel response
more accurately. However, RHI was higher in patients
with more lacunes, which would not be expected. This
may be as RHI and FMD are not measuring the same
vascular parameter, or that changes in RHI are related
to shape of the response to hyperaemia rather than the
maximum response.29
Indices of arterial stiﬀness (as measured by PWV27)
and atherosclerosis (as measured by carotid-intima
media thickness load30) were also linked to more
lacunes and atrophy, despite a lack of co-existent vas-
cular disease or macroscopic evidence of atherosclerosis
in our patients. This may indicate that a combination of
large vessel disease resulting from smoking and hyper-
lipidaemia, and small vessel dysfunction, caused by
CADASIL, is particularly damaging: alternatively,
since there was no macroscopic radiological or clinical
evidence of atherosclerosis, these indices may be abnor-
mal as a consequence of CADASIL small vessel arter-
iopathy. Clearly there are complex interactions between
these factors which require larger group numbers to
unravel. A recent longitudinal study reported that
smoking worsened disease outcomes, but age and
hypertension had little eﬀect on disease progression.12
CADASIL is characterised by damage to smooth
muscle cells.4 Reduced CBF and attenuated CVR
have been demonstrated to precede histological changes
in mouse models.31 Whilst models fail to recapitulate
human CADASIL entirely, they suggest that smooth
muscle cell dysfunction leads to the development of
brain lesions. Capillary dysfunction, secondary to loss
of pericytes32 may also have a role.3 In human studies,
reduced CBF and cerebral blood volume have been
associated with worse clinical or radiological out-
comes,6,33 and impaired CVR has been associated
with disability.34 Despite the role of CVR in the devel-
opment of manifestations of CADASIL remaining
unclear, it has already been used as an endpoint in
therapeutic trials of oral acetazolamide, which
improved CVR and CBF,35 and atorvastatin, which
did not alter cerebral haemodynamics.36 This study
provides more evidence that it may have a role in
pathophysiology, and hence potential as a biomarker
of disease progression.
The role of hypertension in CADASIL remains
unclear. We found patients with lower resting systolic
BP had lower CVR. A lower BP proﬁle has previously
been described in CADASIL due to reduced daytime
values,37 and MABP was positively correlated to global
cognitive impairment. Therefore low BP may either be
harmful or reﬂect more severe disease.37 Alterations in
BP may be explained by central damage to circadian
control, or to autonomic centres. An alternative
hypothesis is that tissue in CADASIL has increased
capillary transit time heterogeneity (CTTH), and
reduced CBF (and perhaps BP) is a protective mechan-
ism to minimise heterogeneity and preserve oxygen
extraction.38 BP management of these patients needs
further investigation. We did not correct for change
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in BP during reactivity measurements as we did not
measure BP in the MRI scanner, and only twice
during hypercapnia challenge. Lack of correction for
BP ﬂuctuations during hypercapnia could confound
CBF and CVR, even if it does not correlate with
reactivity measures.
Strengths of this study include a CADASIL popula-
tion with a wide age range, and a number of aﬀected
exons, who lacked conventional risk factors for stroke
such as hypertension, diabetes or carotid disease, mean-
ing that cerebral pathology is likely to reﬂect
CADASIL solely. All tests were performed by a
single, trained, rater, and attendance at 100% of visits
was achieved. High resolution MRI scans were avail-
able, with hypercapnic challenge undertaken with
monitoring of inspired and expired gases.
There are limitations to our study. The number of
subjects is small, largely due to the comprehensive
assessment required. Multiple exploratory univariate
comparisons may over-estimate the strength of rela-
tionships, and adjustment for confounding by variables
that are potentially highly correlated in a multivariate
model was not possible due to the small sample size.
The multimodal analysis of vascular function has not
previously been done, and we therefore did not deﬁne a
single prior hypothesis regarding these relationships.
Future studies could use these data to select test
panels appropriate to the clinical question. Subjects
were asked to refrain from nicotine, caﬀeine and alco-
hol, but we did not fast patients or stop any medication.
Testing took place at multiple visits over a maximum
three-month period, although no subject experienced a
new stroke or hospital admission between visits. There
was some variation in the time of testing between sub-
jects. We cannot exclude these factors are relevant to
our results. Whilst performing all tests on the same day
would be ideal, both MRI and cognitive tests are ardu-
ous for patients, and completion of protocol procedures
would likely have been lower.
Hypercapnia challenge MRI is a challenging tech-
nique and CVR was calculable in only 13 patients, pre-
dominantly due to inaccurate end-tidal CO2 assessment
secondary to poor mask seal. Other gas delivery meth-
ods are available, and may prove more reliable39 but
are more expensive and may be less tolerable.
Dichotomisation of radiological variables by their
median was performed to simply the clinical interpret-
ation12 and is arbitrary; however, it is unlikely that the
relationships that exist between vascular dysfunction
and damage are linear, rather there may be a threshold
at which impaired vasoreactivity has a deleterious
eﬀect.
The lack of a control group limits interpretation of
our results to some extent, but selecting an appropriate
control population is challenging. We know
symptomatic CADASIL patients diﬀer from age-
matched controls, and a control group from this popu-
lation would be unlikely to address key components of
this study to explore the relationships of vasoreactivity
and radiological or clinical markers of cerebral small
vessel disease, since these features are rarely present in
healthy individuals. Patients with sporadic small vessel
disease are heterogenous, typically older, and with mul-
tiple confounding co-morbidities and medications, and
thus present other concerns as a valid control popula-
tion. Screening control populations for potentially
pathogenic mutations in NOTCH3 or other relevant
genes presents ethical issues when this is undertaken
solely for research, and cannot take into account the
potential presence of currently unknown pathogenic
mutations. Asymptomatic CADASIL patients diag-
nosed via genetic screening might provide a useful com-
parator population, but few asymptomatic patients
take up screening in this disease.40
Impaired vasoreactivity is associated with increased
numbers of lacunes, an important established correlate
of clinical severity. Large vessel disease also plays a
crucial role. To establish if vasoreactivity could func-
tion as a potential biomarker in CADASIL, as well as
better understanding its place in pathophysiology lon-
gitudinal analysis is required. In light of our ﬁnding of
low systolic BP being associated with lower CVR,
assessment of the role of autonomic dysregulation in
CADASIL pathophysiology may be warranted.
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